| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$180 |
Proposed issue of securities - LDX
|
27 Mar 2026 10:08AM |
$0.265 |
$0.195 |
fallen by
26.42%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$180 |
Proposed issue of securities - LDX
|
27 Mar 2026 10:08AM |
$0.265 |
$0.195 |
fallen by
26.42%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$180 |
Lumos completes $20m placement and launches SPP
|
27 Mar 2026 10:08AM |
$0.265 |
$0.195 |
fallen by
26.42%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos completes A$20m institutional placement
- Launches Share Purchase Plan (SPP) to raise A$2m
- Proceeds to support US commercialization of FebriDx
- Funds to expand manufacturing and marketing in the US
- CLIA waiver received for FebriDx by US FDA
- Placement involved issue of 88.9m new shares
- Placement price at A$0.225 per share
- SPP shares offered at the same price as Placement
- Bookrunners were MST, Barrenjoey, and Foster Stockbroking
- Webinar to be conducted for shareholders about SPP
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$180 |
US FDA Grants CLIA Waiver for FebriDx
|
27 Mar 2026 10:08AM |
$0.265 |
$0.195 |
fallen by
26.42%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- US FDA grants CLIA waiver for FebriDx.
- Triggers milestone payments of US$5.5 million.
- Expands FebriDx's market opportunity to over US$1 billion.
- Allows FebriDx to be used in 300,000 locations across the US.
- Positioned to reach 80 million patients per year in the US.
- Broadens FebriDx's applicability to primary care and urgent care settings.
- Significant commercial achievement for Lumos Diagnostics.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lachlan Star Limited (LSA) ORDINARY FULLY PAID |
Materials |
$77 |
Lachlan Star completes acquisition of New Waverley Project
|
27 Mar 2026 10:06AM |
$0.145 |
$0.210 |
risen by
44.83%
|
|
LSA - Price-sensitive ASX Announcement
Full Release
Key Points
- Lachlan Star Limited completed the acquisition of the New Waverley Gold Project.
- The project is located in the Norseman region of Western Australia.
- Lachlan Star now holds a 90% interest in the project.
- The acquisition involved a cash payment of $150,000 and the issuance of 12.5 million shares.
- 50% of the issued shares are under voluntary escrow for 12 months.
- A maiden diamond drilling program is scheduled to commence soon.
- The geological model suggests potential for a high-grade quartz reef system.
- The drilling program aims to test key structural positions and gold-rich quartz veins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$5,952 |
Valiant Gold Lists on the ASX
|
27 Mar 2026 10:03AM |
$5.280 |
$6.300 |
risen by
19.32%
|
|
| Valiant Gold Limited (VAL) ORDINARY FULLY PAID |
Materials |
$93 |
WGX: Valiant Gold Lists on the ASX
|
27 Mar 2026 10:03AM |
$0.250 |
$0.310 |
risen by
24%
|
|
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$292 |
Lodgment of Amended Delaware Charter and Associated Form 8-K
|
27 Mar 2026 10:02AM |
$0.645 |
$0.650 |
risen by
0.78%
|
|
| Highfield Resources Limited (HFR) ORDINARY FULLY PAID |
Materials |
$27 |
Annual Report to shareholders
|
27 Mar 2026 9:59AM |
$0.021 |
$0.056 |
risen by
166.67%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$3,442 |
Proposed issue of securities - 4DX
|
27 Mar 2026 9:59AM |
$6.280 |
$5.840 |
fallen by
7.01%
|
|
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$135 |
Pause in Trading
|
27 Mar 2026 9:59AM |
$0.770 |
$0.780 |
risen by
1.30%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement of a pause in trading of 6K Additive, Inc. securities.
- ASX market release dated 27/03/2026.
- The pause is pending a further announcement.
- The announcement was made by Dale Wang from ASX Listings Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Westgold Resources Limited (WGX) ORDINARY FULLY PAID |
Materials |
$5,952 |
Notification regarding unquoted securities - WGX
|
27 Mar 2026 9:58AM |
$5.540 |
$6.300 |
risen by
13.72%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$1,259 |
PKD - Presentation at World Congress of Nephrology
|
27 Mar 2026 9:58AM |
$1.170 |
$1.280 |
risen by
9.40%
|
|
| Highfield Resources Limited (HFR) ORDINARY FULLY PAID |
Materials |
$27 |
Corporate Governance Statement and Appendix 4G
|
27 Mar 2026 9:58AM |
$0.021 |
$0.056 |
risen by
166.67%
|
|
| Great Southern Mining Limited (GSN) ORDINARY FULLY PAID |
Materials |
$31 |
Cleansing Notice
|
27 Mar 2026 9:57AM |
$0.026 |
$0.027 |
risen by
3.85%
|
|
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$292 |
Appendix 4G and Corporate Governance Statement
|
27 Mar 2026 9:57AM |
$0.650 |
$0.650 |
fallen by
0%
|
|
| Spacetalk Ltd (SPA) ORDINARY FULLY PAID |
Information Technology |
$7 |
Proposed issue of securities - SPA
|
27 Mar 2026 9:57AM |
$0.075 |
$0.059 |
fallen by
21.33%
|
|
| Spacetalk Ltd (SPA) ORDINARY FULLY PAID |
Information Technology |
$7 |
Spacetalk Raises $6.0 million and Appointment of Director
|
27 Mar 2026 9:57AM |
$0.075 |
$0.059 |
fallen by
21.33%
|
|
SPA - Price-sensitive ASX Announcement
Full Release
Key Points
- Spacetalk Ltd to raise $6 million via two-tranche placement.
- Tranche 1 to raise ~$941,683, Tranche 2 to raise ~$5,072,117 pending approval.
- Funds to enhance Spacetalk app and cover inventory, MVNO costs.
- Andrew Grover appointed as Non-Executive Director.
- Placement managed by Taurus Capital Group, to receive a 6% fee.
- Shareholder meeting in May 2026 for Tranche 2 approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Syrah Resources Limited (SYR) ORDINARY FULLY PAID |
Materials |
$206 |
Completion of Institutional Entitlement Offer
|
27 Mar 2026 9:57AM |
$0.145 |
$0.120 |
fallen by
17.24%
|
|
SYR - Price-sensitive ASX Announcement
Full Release
Key Points
- Successful completion of the Institutional Entitlement Offer.
- The offer is fully underwritten with a 1 for 1.32 pro rata structure.
- A$44 million raised from the institutional component.
- A$61 million expected from the retail component.
- New shares priced at A$0.105 each.
- Settlement and allotment scheduled for early April 2026.
- Macquarie Capital (Australia) Limited is the lead manager and underwriter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$21 |
Operations Update - February 2026
|
27 Mar 2026 9:56AM |
$0.062 |
$0.058 |
fallen by
6.45%
|
|
BAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Bass Oil Limited reported February 2026 operations update.
- Total sales revenue for February was A$266,290, with delays in Cooper Basin sales.
- Indonesian operations averaged 142 barrels of oil per day, unaffected by delays.
- Total production for the month was 6,152 barrels.
- Secured $3.5 million grant for Kiwi gas field development.
- Santos-led Cooper Basin JV is advancing resource commercialization.
- Drilling of Jack Lake 8 well was successful, contributing to commercialization efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Steadfast Group Limited (SDF) ORDINARY FULLY PAID |
Financials |
$4,815 |
Appendix 3Y - Joan Cleary and Greg Rynenberg
|
27 Mar 2026 9:56AM |
$4.150 |
$4.330 |
risen by
4.34%
|
|
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$3,442 |
CE Mark for CTVQ and $83M placement to fund EU expansion
|
27 Mar 2026 9:55AM |
$6.280 |
$5.840 |
fallen by
7.01%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- 4DMedical's CT:VQ™ receives CE Mark certification for EU commercialization.
- $83 million private placement completed to fund EU expansion at $5.90 per share.
- CE Mark enables immediate commercial engagement with EU healthcare providers.
- The EU market is significant for CT:VQ™ due to its advanced imaging infrastructure.
- CT:VQ™ offers a non-contrast, CT-based ventilation-perfusion imaging solution.
- Placement results in a 2.45% increase in shares on issue.
- Bell Potter Securities Limited acted as Lead Manager for the placement.
- Proforma cash balance is $289 million as of 31 December 2025.
- CT:VQ™ already in use at leading U.S. Academic Medical Centers.
- The placement supports strategic growth including potential acquisitions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vanguard Global Value Equity Active ETF (Managed Fund) (VVLU) |
Financials |
$1,105 |
Estimated Distribution Announcement
|
27 Mar 2026 9:55AM |
$77.920 |
$78.150 |
risen by
0.30%
|
|
| Vanguard Global Minimum Volatility Active ETF (Managed Fund) (VMIN) |
Financials |
$14 |
Estimated Distribution Announcement
|
27 Mar 2026 9:55AM |
$63.980 |
$63.250 |
fallen by
1.14%
|
|
| Great Southern Mining Limited (GSN) ORDINARY FULLY PAID |
Materials |
$31 |
Application for quotation of securities - GSN
|
27 Mar 2026 9:55AM |
$0.026 |
$0.027 |
risen by
3.85%
|
|
Call 1300 880 160
Start a chat
Schedule a call
